APA (7th ed.) Citation

Smeijer, J. D., Kohan, D. E., Rossing, P., Correa-Rotter, R., Liew, A., Tang, S. C., . . . Lambers Heerspink, H. J. (2023). Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease. Cardiovascular Diabetology, 22(1), 1. https://doi.org/10.1186/s12933-023-01964-8

Chicago Style (17th ed.) Citation

Smeijer, J. David, et al. "Insulin Resistance, Kidney Outcomes and Effects of the Endothelin Receptor Antagonist Atrasentan in Patients with Type 2 Diabetes and Chronic Kidney Disease." Cardiovascular Diabetology 22, no. 1 (2023): 1. https://doi.org/10.1186/s12933-023-01964-8.

MLA (9th ed.) Citation

Smeijer, J. David, et al. "Insulin Resistance, Kidney Outcomes and Effects of the Endothelin Receptor Antagonist Atrasentan in Patients with Type 2 Diabetes and Chronic Kidney Disease." Cardiovascular Diabetology, vol. 22, no. 1, 2023, p. 1, https://doi.org/10.1186/s12933-023-01964-8.